Sorafenib-Induced Acute Generalized Exanthematous Pustulosis
Citation: Cortese A, Pancetti S, Pressiani T, et al. Sorafenib-Induced Acute Generalized Exanthematous Pustulosis. Dermatol Pract Concept. 2023;13(2):e2023130. DOI: https://doi.org/10.5826/dpc.1302a130
Accepted: November 17, 2022; Published: April 2023
Copyright: ©2023 Cortese et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.
Funding: None.
Competing interests: None.
Authorship: All authors have contributed significantly to this publication.
Corresponding author: Andrea Cortese, MD, Dermatology, Humanitas Research Hospital – IRCCS, Via A. Manzoni 56, 20089 Rozzano (MI), Italy. E-mail: andreacortese08@gmail.com
Abstract
References
1. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-119. DOI: 10.1034/j.1600-0560.2001.028003113.x. PMID: 11168761.
2. Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989-996. DOI: 10.1111/j.1365-2133.2007.08156.x. PMID: 17854366.
3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. DOI: 10.1038/clpt.1981.154. PMID: 7249508.
4. Bracarda S, Ruggeri EM, Monti M, et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol. 2012;82(3):378-386. DOI: 10.1016/j.critrevonc.2011.08.005. PMID: 21944842.
5. Liang CP, Yang CS, Shen JL, Chen YJ. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma. Br J Dermatol. 2011;165(2):443-445. DOI: 10.1111/j.1365-2133.2011.10377.x. PMID: 21495998.
6. Pretel M, Iñarrairaegui M, Lera JM, Aguado L, Idoate MA. Acute generalized exanthematous pustulosis induced by sorafenib. JAMA Dermatol. 2014;150(6):664-666. DOI: 10.1001/jamadermatol.2013.6924. PMID: 24671701.
7. Alegre-Sánchez A, de Perosanz-Lobo D, Pinilla-Pagnon I, Muñoz-Zato E. Sorafenib-induced Acute Generalized Exanthematous Pustulosis: An Increasing Association? Actas Dermosifiliogr. 2017;108(6):599-601. DOI: 10.1016/j.ad.2016.11.018. PMID: 28262110.